Emergent BioSolutions Reports First Quarter 2024 Financial R

First Quarter 2024 Total Revenues of $300.4 million, above the prior guidance rangeFirst Quarter 2024 Net Income of $9.0 million and Adjusted EBITDA of $66.9 millionUpdates FY 2024 guidance ...

Related Keywords

United States , Canada , China , Canadian , Canton , Josephc Papa , Joe Papa , Assal Hellmer , Emergent Biosolutions Inc , Exchange Commission , Development Expenses , Company Camden , Twitter , Linkedin , Us Department Of Defense , Instagram , Company Canton , First Quarter , Net Income , Diluted Share , Segment Gross Margin , Segment Adjusted Gross Margin , Anthrax Vaccine Adsorbed , Baltimore Bayview Manufacturing , Medical Countermeasure , Commercial Products , Bavarian Nordic , Nasal Spray , Commercial Product , Ended March , United States Securities , Adjusted Gross Margin , Adjusted Net Income , Total Segment Revenues , Total Revenues , Total Segment Gross Margin , Total Segment , Total Segment Adjusted Gross Margin , Consolidated Statements , Private Securities Litigation Reform Act , Botulism Antitoxin Heptavalent , Reactive Skin Decontamination Lotion Kit , Senior Unsecured Notes , Emergent Biosolutions , Vice President , Chief Financial , Months Ended March , Gross Margin , Net Loss Forecast , Adjusted Net Loss , Forecasted Total Revenues , Forecasted Total Segment Revenues , Forecasted Segment , Markets ,